CNBX Pharmaceuticals Reports Critical Liquidity Crisis, Going Concern Doubt, and Massive Dilution

summarizeSummary

CNBX Pharmaceuticals reported critically low cash reserves, a significant net loss, and ongoing substantial doubt about its ability to continue as a going concern, coupled with massive share dilution from convertible debt.

check_boxKey Events

• Critical Cash Shortage

  Cash and cash equivalents plummeted to $12,154 as of February 28, 2026, down from $15,111 on August 31, 2025. The company projects a minimum of $1,000,000 in expenses for the next twelve months, indicating a severe funding gap.

• Substantial Doubt About Going Concern

  Management explicitly disclosed 'substantial doubt about the ability of the Company to continue as a going concern' due to cumulative losses and an inability to generate revenue.

• Increased Net Loss

  The net loss for the six months ended February 28, 2026, increased to $(157,817) compared to $(104,140) for the same period in the prior year.

• Massive Share Dilution from Convertible Debt

  During the period ended February 28, 2026, the company issued 571,805,889 shares from convertible loans and interest for a total of $120,562. Subsequently, on March 17, 2026, an additional 100,000,000 shares were issued for only $8,000, representing extreme dilution.

auto_awesomeAnalysis

CNBX Pharmaceuticals Inc. faces an immediate and severe liquidity crisis, with only $12,154 in cash against projected expenses of $1,000,000 for the next twelve months. The company explicitly states 'substantial doubt about the ability of the Company to continue as a going concern.' This dire financial position is exacerbated by ongoing, highly dilutive financing activities, where hundreds of millions of shares are being issued for minimal capital, significantly impacting existing shareholders. The company's ability to survive is entirely dependent on securing additional capital, which has proven challenging and costly.